“Big Four” professional services firm Deloitte is moving away from “simply covering a GLP-1 prescription” for employees’ weight loss, pivoting to a lifestyle program in 2027, according to a statement shared with Becker’s Nov. 13.
Deloitte will continue GLP-1 coverage for diabetes or other covered medical conditions. However, the company is also updating its benefits more broadly, including “select modifications where the rates of cost growth are no longer sustainable.”
Starting in January 2027, rather than direct coverage for weight loss, Deloitte employees can access direct-from-manufacturer GLP-1 drug pricing and a company contribution for each prescription as part of the firm’s lifestyle support program. This program offers coaching, nutritional support and clinical guidance.
The share of U.S. employers covering GLP-1s for weight loss dropped for the first time in three years, going from 57% to 53%, according to the 2026 Best Practices in Healthcare Survey from WTW. Even healthcare employers have been scaling back this benefit. High-cost drugs, including GLP-1s, have been a top driver of employer healthcare costs.
